Entry Point Capital, LLC Taysha Gene Therapies, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding TSHA
# of Institutions
108Shares Held
136MCall Options Held
65.4KPut Options Held
41.7K-
Rtw Investments, LP New York, NY18.8MShares$37.8 Million0.7% of portfolio
-
Avoro Capital Advisors LLC New York, NY18.7MShares$37.5 Million0.57% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$23.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$21.9 Million0.37% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$18.1 Million2.21% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $97.2M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...